Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Paycom Software Inc (PAYC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Paycom Software Inc — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $356.44 (market cap $9.39B), while Paycom Software Inc trades at $211 (market cap $9.62B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock and Paycom Software Inc are close in size by market cap, and Paycom Software Inc pays a 0.7% dividend while Bio-Rad Laboratories, Inc. Class A Common Stock pays none. Which is the better fit depends on your goals.
| BIO | PAYC | |
|---|---|---|
Market Cap | $9.39B | $9.62B |
Sector | Health | Technology |
52-Week High | $356.25 | $233.89 |
52-Week Low | $241.71 | $113.59 |
Enterprise Value | $9.14B | $10.41B |
Dividend Yield | — | 0.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $352.47, up 2.93% today, near its consensus price target of $350. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Fundamentally, Q2 2026 earnings beat expectations at $2.62 EPS, but revenue remains flat at $2.58 billion in 2025. The company has returned to profitability with a net income of $759.9 million after losses in prior years, supported by a solid gross margin of 51.9%.
The outlook is cautiously optimistic with analyst consensus at Buy (53.85%), but high P/E of 43.18 suggests premium valuation. Risks include revenue stagnation and sensitivity to academic research funding. Upside is supported by positive cash flow trends and institutional accumulation, yet investors should weigh valuation against growth prospects.
Paycom Software (PAYC) trades at $214.94, down 0.48% on the day, with a bullish technical signal supported by moving averages. The stock exhibits strong fundamentals, including a 22.78% net income margin and consistent earnings beats, most recently with Q2 2026 EPS of $2.78 versus $2.38 expected. Recent news highlights AI-driven demand and raised 2026 guidance, fueling positive sentiment.
Outlook remains favorable due to robust profitability and growth initiatives, though risks include high valuation multiples and competitive pressures. Analyst consensus is mixed with a $219.22 price target, suggesting modest upside potential from current levels amid balanced buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Paycom Software Inc
Paycom is a fast-growing provider of payroll and human capital management, or HCM, software primarily targeting clients with 50-10,000 employees in the United States. Paycom was established in 1998 and services about 18,000 clients as of 2021, based on parent company grouping. Alongside its core payroll software, Paycom offers various HCM add-on modules, including time and attendance, talent management, and benefits administration.
Read more on PAYC →
